• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses.

作者信息

Cinkilic Okan, Anft Moritz, Blazquez-Navarro Arturo, Meister Toni L, Roch Toralf, Stervbo Ulrik, Pfaender Stephanie, Westhoff Timm H, Babel Nina

机构信息

Dialysezentrum Schwerte, Schwerte, Germany.

Center for Translational Medicine and Immune Diagnostics Laboratory, Medical Department I, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.

出版信息

Kidney Int. 2022 Jun;101(6):1287-1289. doi: 10.1016/j.kint.2022.03.005. Epub 2022 Mar 14.

DOI:10.1016/j.kint.2022.03.005
PMID:35301007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8920472/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26b4/8920472/8522a925cfa8/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26b4/8920472/8522a925cfa8/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26b4/8920472/8522a925cfa8/gr1_lrg.jpg

相似文献

1
Inferior humoral and sustained cellular immunity against wild-type and omicron variant of concern in hemodialysis patients immunized with 3 SARS-CoV-2 vaccine doses compared with 4 doses.与接种4剂相比，接种3剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的血液透析患者对野生型和奥密克戎变异株的体液免疫较低，细胞免疫持续存在。
Kidney Int. 2022 Jun;101(6):1287-1289. doi: 10.1016/j.kint.2022.03.005. Epub 2022 Mar 14.
2
Inferior cellular and humoral immunity against Omicron and Delta variants of concern compared with SARS-CoV-2 wild type in hemodialysis patients immunized with 4 SARS-CoV-2 vaccine doses.在接受4剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗免疫的血液透析患者中，与SARS-CoV-2野生型相比，针对奥密克戎和德尔塔变异株的细胞免疫和体液免疫较低。
Kidney Int. 2022 Jul;102(1):207-208. doi: 10.1016/j.kint.2022.05.004. Epub 2022 May 14.
3
Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.评估 2 至 3 剂 BNT162b2 mRNA COVID-19 疫苗后针对 SARS-CoV-2 变异株的中和抗体反应。
JAMA Netw Open. 2022 May 2;5(5):e2210780. doi: 10.1001/jamanetworkopen.2022.10780.
4
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
5
Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients.在血液透析患者中，第三次接种 BNT162b2 疫苗前后对 B.1.617.2（德尔塔）变异株的中和抗体活性。
Front Immunol. 2022 Mar 4;13:840136. doi: 10.3389/fimmu.2022.840136. eCollection 2022.
6
A Highly Conserved Peptide Vaccine Candidate Activates Both Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains.一种高度保守的多肽疫苗候选物能激活针对 SARS-CoV-2 变异株的体液和细胞免疫。
Front Immunol. 2021 Dec 7;12:789905. doi: 10.3389/fimmu.2021.789905. eCollection 2021.
7
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant.mRNA 加强免疫可引发针对 SARS-CoV-2 奥密克戎变异株的强效中和血清活性。
Nat Med. 2022 Mar;28(3):477-480. doi: 10.1038/s41591-021-01676-0. Epub 2022 Jan 19.
8
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis.评估严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗（BNT126b2）在维持性血液透析患者中的细胞免疫原性和体液免疫原性。
EBioMedicine. 2021 Sep;71:103567. doi: 10.1016/j.ebiom.2021.103567. Epub 2021 Aug 26.
9
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.加强剂对康复的 COVID-19 患者血清中和针对奥密克戎变异株的活性：BNT162b2 和科兴疫苗的效果。
EBioMedicine. 2022 May;79:103986. doi: 10.1016/j.ebiom.2022.103986. Epub 2022 Apr 8.
10
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection.一剂 mRNA 疫苗接种在 SARS-CoV-2 感染 18 个月后诱导广泛的体液和细胞免疫。
BMC Med. 2022 May 4;20(1):181. doi: 10.1186/s12916-022-02383-4.

引用本文的文献

1
Longitudinal Characterization of SARS-CoV-2 Immunity in Hemodialysis Patients Post Omicron.奥密克戎变异株感染后血液透析患者的新型冠状病毒2型免疫纵向特征分析
Kidney Int Rep. 2024 Nov 19;10(2):406-415. doi: 10.1016/j.ekir.2024.11.012. eCollection 2025 Feb.
2
Blood unconjugated bilirubin and tacrolimus are negative predictors of specific cellular immunity in kidney transplant recipients after SAR-CoV-2 inactivated vaccination.血未结合胆红素和他克莫司是肾移植受者 SARS-CoV-2 灭活疫苗接种后特异性细胞免疫的负预测因子。
Sci Rep. 2023 May 4;13(1):7263. doi: 10.1038/s41598-023-29669-8.
3
Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.

本文引用的文献

1
A Vector-Based Vaccine Dose After 3 Doses of mRNA-Based COVID-19 Vaccination Does Not Substantially Improve Humoral SARS-CoV-2 Immunity in Renal Transplant Recipients.在接受3剂基于mRNA的新冠疫苗接种后，接种一剂基于载体的疫苗并不能显著提高肾移植受者的体液严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫力。
Kidney Int Rep. 2022 Apr;7(4):932-934. doi: 10.1016/j.ekir.2022.01.1068. Epub 2022 Feb 1.
2
Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series.肾移植受者对第四剂信使核糖核酸新冠疫苗的抗体反应：病例系列
Ann Intern Med. 2022 Mar;175(3):455-456. doi: 10.7326/L21-0598. Epub 2022 Jan 11.
3
免疫抑制治疗和新型冠状病毒2型疫苗类型对慢性肾脏病或肾脏替代治疗患者三次接种疫苗后抗体水平的影响
Clin Kidney J. 2022 Nov 24;16(3):528-540. doi: 10.1093/ckj/sfac249. eCollection 2023 Mar.
4
Trajectory of Humoral Responses to Two Doses of ChAdOx1 nCoV-19 Vaccination in Patients Receiving Maintenance Hemodialysis.接受维持性血液透析的患者对两剂ChAdOx1 nCoV-19疫苗接种的体液免疫反应轨迹
Microbiol Spectr. 2023 Feb 21;11(2):e0344522. doi: 10.1128/spectrum.03445-22.
5
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant.深入分析针对 SARS-CoV-2 和奥密克戎变异株的异源初免-加强-加强疫苗方案中的 T 细胞免疫和抗体反应。
Front Immunol. 2022 Dec 21;13:1062210. doi: 10.3389/fimmu.2022.1062210. eCollection 2022.
6
Immunogenicity Rates after SARS-CoV-2 Three-Dose Vaccination in Patients under Dialysis: A Systematic Review and Meta-Analysis.透析患者接种三剂严重急性呼吸综合征冠状病毒2疫苗后的免疫原性率：一项系统评价和荟萃分析。
Vaccines (Basel). 2022 Dec 2;10(12):2070. doi: 10.3390/vaccines10122070.
7
Immune responses to SARS-CoV-2 in dialysis and kidney transplantation.透析和肾移植中对严重急性呼吸综合征冠状病毒2的免疫反应。
Clin Kidney J. 2022 Jul 27;15(10):1816-1828. doi: 10.1093/ckj/sfac174. eCollection 2022 Oct.
8
SARS-CoV-2 vaccination in haemodialysis patients: Insides from a prospective study comparing mRNA and viral vector vaccines.血液透析患者中的新型冠状病毒2型疫苗接种：一项比较信使核糖核酸疫苗和病毒载体疫苗的前瞻性研究内情
Lancet Reg Health Eur. 2022 Sep 13;21:100491. doi: 10.1016/j.lanepe.2022.100491. eCollection 2022 Oct.
9
SARS-CoV-2 neutralizing antibody response after three doses of mRNA1273 vaccine and COVID-19 in hemodialysis patients.三剂mRNA1273疫苗接种后血液透析患者的SARS-CoV-2中和抗体反应及COVID-19情况
Front Nephrol. 2022;2. doi: 10.3389/fneph.2022.926635. Epub 2022 Jul 22.
10
Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.血液透析患者第四次接种疫苗后对新型冠状病毒变异株德尔塔和奥密克戎BA.1的中和作用增强
Vaccines (Basel). 2022 Aug 16;10(8):1328. doi: 10.3390/vaccines10081328.
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant.
基于信使核糖核酸的新冠病毒疫苗加强针可诱导针对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和免疫力。
Cell. 2022 Feb 3;185(3):457-466.e4. doi: 10.1016/j.cell.2021.12.033. Epub 2022 Jan 6.
4
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.在英国，用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂（加强针）接种 7 种 COVID-19 疫苗的安全性和免疫原性（COV-BOOST）：一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
5
Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant.评估 4 剂 SARS-CoV-2 信使 RNA 疫苗在实体器官移植受者中的效果。
JAMA Netw Open. 2021 Nov 1;4(11):e2136030. doi: 10.1001/jamanetworkopen.2021.36030.